Goldman Sachs’s Akoya BioSciences AKYA Stock Holding History

Goldman Sachs’s Portfolio AKYA Stock Details AKYA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-173,441	Closed	-$225K	–	6309
2025 Q2	$225K	Buy	173,441 +73,661	+74%	+$88.6K	﹤0.01%	5600
2025 Q1	$139K	Buy	99,780 +19,475	+24%	+$42.6K	﹤0.01%	5720
2024 Q4	$184K	Buy	80,305 +27,416	+52%	+$72.6K	﹤0.01%	5665
2024 Q3	$144K	Buy	52,889 +39,563	+297%	+$96.6K	﹤0.01%	5522
2024 Q2	$31.2K	Buy	13,326 +993	+8%	+$3.17K	﹤0.01%	5493
2024 Q1	$57.8K	Buy	12,333 +2,232	+22%	+$11.6K	﹤0.01%	5309
2023 Q4	$8.01M	Sell	10,101 -8,848	-47%	-$36.8K	﹤0.01%	2730
2023 Q3	$261K	Buy	+18,949	New	+$109K	﹤0.01%	4952

Goldman Sachs's AKYA Position: Q3 2025 in Review

Goldman Sachs sold out of Akoya BioSciences (AKYA) in Q3 2025, closing a stake of 173,441 shares — an estimated $225K sold.

Goldman Sachs first reported a position in AKYA in Q3 2023 and held it in 8 quarters. The position peaked at $8.01M in Q4 2023. 0 funds tracked by Wall St. Rank hold AKYA as of Q3 2025.

Goldman Sachs reported no remaining Akoya BioSciences position as of Q3 2025 after selling out during the quarter.
Goldman Sachs sold 173,441 Akoya BioSciences shares in Q3 2025, an estimated $225K.
Goldman Sachs first reported a position in Akoya BioSciences in Q3 2023 and held it in 8 quarters.
Goldman Sachs's Akoya BioSciences position peaked at $8.01M in Q4 2023.
0 funds tracked by Wall St. Rank held Akoya BioSciences as of Q3 2025.

Based on Goldman Sachs's 13F filing for Q3 2025, filed 14 Nov 2025.